Member Info for Jimzi

see RNS - 12th - all converted.

Book square - just PIs crapping themselves.

Another SB purchase looming.

Just to annoy COY, I have added 100k spreadbet at 11.04.

Why not - but unless it’s made of gold; it may have a limited impact. ATB

If there was an overhang, you would be able to buy 500k within the ask.
Currently RSP is 11.05 v 14.89 ergo no overhang.

I think most PIs are a bit punch drunk after the last few sessions of mega wild swings courtesy of CNs and small float.
I'm in an accumulation phase now - the runway is now clear!

GL

No overhang gents - can shift 500k above 11p

MMs are strange - couldn't buy over 100 shares today atm or yesterday at all.

It’s great value if you have patience- this Covid trading mania/ volatility makes short term forecasts impossible- so just be long and strong. This madness will end at some point. Don’t ask me when cause I’m as confused as the next man.

someone on Twitter got the message.

Clear from Fridays interview the genomic data will be kept under the #orph umbrella. Data information providers like Iqvia trading on 30 x earnings and we want this for our business. Data is pure profit and and value creative to the core vaccine business.

A few bullet delayed sells on opening and now the BB starts picking holes.
If they were delayed buys, the BB would be totally reverse.

Too many sheep being swayed by 5 mins of trading.

He does interviews to update holders and prospective holders.

UPDATE ergo meaning what has changed [in what is a changing world by the day]

Your right Moni - HVO at its peak was valued at around 282m - now it may have overshot its true value with Woody gobbling away but that was 2.5 years ago - now its a different monster plus 2 other companies making it one of the safest out there which given the massive volatility in the current markets may attract some new researched investors.
Best of all, the placing bogyman has run away with a flea in his ear & divis are being discussed.

Demon is spot on here:
" We’re not in a position where we need to sell, we hold the keys to the safe so let’s add multiples of recurring revenue to our P&L year on year. With all the data we hold, this will open up multiple avenues to further recurring revenues. Really exciting and our PE will change from being a 3 x“boring service company” to a mix of this plus 9 x data licensing company."

Gets even better though as the recurring revenue is in fact recurring 100% net profit. [less minimal admin costs]on an owned risk free asset.
Selling is a nice one off but it doesn't use the mcap multiplier that can make this a £1b company

Imutex Nasdaq correct as well - massive potential being the sole universal flu vaccine but not a 100% risk free or owned asset so best to share the risk and profits with a wider shareholder base as a way to proceed as it must.

Very very happy with his presentation and his continuing astute strategy - right man in the right place at the right time.

Nov 11 (Reuters) – PDS Biotechnology Corp :

Pds Biotechnology Reports Financial Results For The Third Quarter 2020 And Provides Business Update
Q3 Loss Per Share $0.23
As Of September 30, 2020, Co's Cash Balance Was About $33.5 Million
Source text for Eikon: ... Further company coverage:

(Reuters.Briefs@thomsonreuters.com;)

© Thomson Reuters Limited. Click for restrictions [see IG data feed]

Current mcap is $49.64m

70% covered by cash.

They are bad at valuing as we are here!!

It has nothing to do with market makers. They don’t care what price there is - they make their cash by their spread and respond to buys and sells. They have no other interest.
Atm we have some traders playing the 50/60 game and fair dos.
Think of us a car with a flat battery. It turns slow then high then slow but doesn’t start. After 4 attempts it suddenly sparks up and off you go - and those that sold thinking it wouldn’t start jump straight back. 8 m free float is like tinderwood - boofff

It is only 1/16th of our portfolio.
No one is looking at the 15/16ths.
They will one day

Great

Bit worrying that I’m more on the ball than the BOD. Maybe they overslept- lmao

missed during the strange day!

FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology
Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company
developing novel cancer therapies and infectious disease vaccines based on the
Company’s proprietary Versamune(®) T-cell activating technology, today
announced that its VERSATILE-002 Phase 2 clinical trial evaluating the
combination of PDS0101 and KEYTRUDA(®) (pembrolizumab) for the first-line
treatment of head and neck cancer that has returned or spread is now open. The
trial is being conducted in collaboration with Merck.

Great news from Pfizer.

Clearly deal sorted some time ago and just awaiting the massive global door openor - FDA.
We have just got off the B road straight to the 6 lane motorway.

Global partnership is totally different to to global distribution agreement- partnerships- akin to a corporate relationship with joint liability-
Sow the seeds but too many here clued up